Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Lung Cancer

  Free Subscription


Articles published in JAMA Oncol

Retrieve available abstracts of 72 articles:
HTML format



Single Articles


    October 2025
  1. LIN JK, Xu Y, Xiang JJ, Singhi EK, et al
    Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer.
    JAMA Oncol. 2025 Oct 2:e253768. doi: 10.1001/jamaoncol.2025.3768.
    PubMed    


    September 2025
  2. ANTONOFF MB, Phillips L, Singhi EK
    Understanding Lung Cancer in Younger People.
    JAMA Oncol. 2025 Sep 25. doi: 10.1001/jamaoncol.2025.3320.
    PubMed    


  3. DI Y, Song Z, Meng L
    Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 Sep 18. doi: 10.1001/jamaoncol.2025.3491.
    PubMed    


  4. BERTOLACCINI L, de Marinis F, Spaggiari L
    Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 Sep 18. doi: 10.1001/jamaoncol.2025.3494.
    PubMed    


  5. GARBO E, Ricciuti B, Cappuzzo F
    Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2025 Sep 18. doi: 10.1001/jamaoncol.2025.3497.
    PubMed    


  6. JONGBLOED M, Bortolot M, Willmann J, Bartolomeo V, et al
    Current Controversies and Challenges in Non-Oncogene-Addicted Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Review.
    JAMA Oncol. 2025 Sep 4. doi: 10.1001/jamaoncol.2025.2891.
    PubMed     Abstract available


    August 2025
  7. ROLLE LD, Crane TE
    Methodological Concerns With Lung Cancer Screening Estimates-Reply.
    JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2581.
    PubMed    


  8. BURUS T, McAfee CR, Hull PC
    Methodological Concerns With Lung Cancer Screening Estimates.
    JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2584.
    PubMed    


    June 2025
  9. MARKS JA, Liu SV
    Navigating Selective Dose Intensification in EGFR-Variant Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 Jun 26. doi: 10.1001/jamaoncol.2025.1768.
    PubMed    


  10. LI H, Chen K, Gong L, Qin J, et al
    High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2025 Jun 26. doi: 10.1001/jamaoncol.2025.1779.
    PubMed     Abstract available


    May 2025
  11. ROLLE LD
    Coding Errors in Study of Lung Cancer Screening Guidelines and Adherence.
    JAMA Oncol. 2025 May 29. doi: 10.1001/jamaoncol.2025.1624.
    PubMed    


  12. MARINELLO A, Ghigna MR, Rotow JK, Adeyelu T, et al
    Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 May 29. doi: 10.1001/jamaoncol.2025.1293.
    PubMed     Abstract available


  13. RICCIUTI B, Fusco F, Cooper A, Garbo E, et al
    Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 May 22. doi: 10.1001/jamaoncol.2025.1115.
    PubMed     Abstract available


  14. HEYWARD J, Lesko CR, Murray JC, Mehta HB, et al
    Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 May 8. doi: 10.1001/jamaoncol.2025.0985.
    PubMed     Abstract available


    April 2025
  15. PIKE LRG, Yu H, Rusthoven CG
    Management of EGFR-Variant and ALK-Positive Non-Small Cell Lung Cancer Brain Metastasis.
    JAMA Oncol. 2025 Apr 3. doi: 10.1001/jamaoncol.2025.0188.
    PubMed    


    March 2025
  16. ROLLE LD, Olazagasti C, Lopes G, Rodriguez E, et al
    USPSTF Lung Cancer Screening Guidelines and Disparities in Screening Adherence.
    JAMA Oncol. 2025 Mar 20. doi: 10.1001/jamaoncol.2025.0230.
    PubMed    


    February 2025
  17. SAAL J, Eckstein M, Ritter M, Brossart P, et al
    Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy.
    JAMA Oncol. 2025;11:154-161.
    PubMed     Abstract available


  18. GODDARD KAB, Feuer EJ, Mandelblatt JS, Meza R, et al
    Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020.
    JAMA Oncol. 2025;11:162-167.
    PubMed     Abstract available


    December 2024
  19. RAKAEE M, Tafavvoghi M, Ricciuti B, Alessi JV, et al
    Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Dec 26. doi: 10.1001/jamaoncol.2024.5356.
    PubMed     Abstract available


    November 2024
  20. MALHOTRA J, Mambetsariev I, Gilmore G, Fricke J, et al
    Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers: A Review.
    JAMA Oncol. 2024 Nov 27. doi: 10.1001/jamaoncol.2024.5218.
    PubMed     Abstract available


  21. CHENG Y, Zhang W, Wu L, Zhou C, et al
    Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.
    JAMA Oncol. 2024 Nov 14. doi: 10.1001/jamaoncol.2024.5019.
    PubMed     Abstract available


  22. CALI DAYLAN AE, Morgensztern D, Waqar SN
    Toripalimab For Extensive-Stage Small Cell Lung Cancer.
    JAMA Oncol. 2024 Nov 14. doi: 10.1001/jamaoncol.2024.4958.
    PubMed    


    October 2024
  23. ASAHINA H, Tsukita Y, Tozuka T
    Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2024 Oct 24. doi: 10.1001/jamaoncol.2024.4757.
    PubMed    


  24. TU H, Zhang Y, You Z
    Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Oct 24. doi: 10.1001/jamaoncol.2024.4754.
    PubMed    


    September 2024
  25. ZHANG L, Li J, Guo L
    Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Sep 26. doi: 10.1001/jamaoncol.2024.4211.
    PubMed    


  26. SORIN M, Prosty C, Spicer JD
    Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2024 Sep 26. doi: 10.1001/jamaoncol.2024.4214.
    PubMed    


  27. HU C
    Stereotactic Body Radiotherapy for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Sep 19. doi: 10.1001/jamaoncol.2024.2905.
    PubMed    


  28. SWAMINATH A, Parpia S, Wierzbicki M, Kundapur V, et al
    Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2024 Sep 19:e243089. doi: 10.1001/jamaoncol.2024.3089.
    PubMed     Abstract available


    August 2024
  29. HONG MH, Choi YJ, Ahn HK, Lim SM, et al
    Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial.
    JAMA Oncol. 2024 Aug 15. doi: 10.1001/jamaoncol.2024.2640.
    PubMed     Abstract available


  30. CHENG H
    The Role of Lazertinib in Patients With EGFR-Variant Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Aug 15. doi: 10.1001/jamaoncol.2024.2607.
    PubMed    


  31. HATTON JN, Kucera J, Seastedt KP, de Andrade KC, et al
    Characterizing Lung Cancer in Li-Fraumeni Syndrome.
    JAMA Oncol. 2024 Aug 1:e242511. doi: 10.1001/jamaoncol.2024.2511.
    PubMed    


  32. LEE JM
    Sublobar Resection vs Lobectomy for High-Risk Stage I Non-Small Cell Lung Carcinoma.
    JAMA Oncol. 2024 Aug 1. doi: 10.1001/jamaoncol.2024.2294.
    PubMed    


  33. ALTORKI N, Wang X, Damman B, Jones DR, et al
    Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Seconday Analysis of a Randomized Clinical Trial.
    JAMA Oncol. 2024 Aug 1:e242491. doi: 10.1001/jamaoncol.2024.2491.
    PubMed     Abstract available


    July 2024
  34. ROSS HJ, Kozono D, Wang XF, Urbanic JJ, et al
    Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
    JAMA Oncol. 2024 Jul 25. doi: 10.1001/jamaoncol.2024.1897.
    PubMed     Abstract available


  35. TSAI CH, Chiang PH
    More Benefits of Tai Chi Than Aerobic Exercise in Patients With Advanced Lung Cancer.
    JAMA Oncol. 2024 Jul 3. doi: 10.1001/jamaoncol.2024.2453.
    PubMed    


  36. TAKEMURA N, Lin CC
    More Benefits of Tai Chi Than Aerobic Exercise in Patients With Advanced Lung Cancer-Reply.
    JAMA Oncol. 2024 Jul 3. doi: 10.1001/jamaoncol.2024.2456.
    PubMed    


    June 2024
  37. CHUN SG, Hu C, Komaki RU, Timmerman RD, et al
    Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    JAMA Oncol. 2024 Jun 27. doi: 10.1001/jamaoncol.2024.1841.
    PubMed     Abstract available


  38. DONG S, Wang Z, Zhang JT, Yan B, et al
    Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.
    JAMA Oncol. 2024 Jun 13. doi: 10.1001/jamaoncol.2024.1779.
    PubMed     Abstract available


    May 2024
  39. CHAUNZWA TL, Qian JM, Li Q, Ricciuti B, et al
    Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy.
    JAMA Oncol. 2024 May 23. doi: 10.1001/jamaoncol.2024.1120.
    PubMed     Abstract available


  40. SORIN M, Prosty C, Ghaleb L, Nie K, et al
    Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.
    JAMA Oncol. 2024;10:621-633.
    PubMed     Abstract available


  41. ROLFO C, Russo A
    The Chemoimmunotherapy Revolution in Resectable NSCLC-The Times They Are A-Changin'.
    JAMA Oncol. 2024;10:569-570.
    PubMed    


    April 2024
  42. NORONHA V, Patil V, Menon N, Shah M, et al
    Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer-Long-Term Results of a Randomized Clinical Trial.
    JAMA Oncol. 2024 Apr 25. doi: 10.1001/jamaoncol.2024.0584.
    PubMed    


  43. RODRIGUES G, Higgins KA, Rimner A, Amini A, et al
    American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Apr 11. doi: 10.1001/jamaoncol.2024.0294.
    PubMed     Abstract available


  44. AKAMATSU H
    Locally Advanced Relapse May Not Be Equal to Stage 3 Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0231.
    PubMed    


  45. TACHIHARA M, Tsujino K
    Locally Advanced Relapse May Not Be Equal to Stage 3 Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0234.
    PubMed    


  46. SZLOSAREK PW, Creelan BC, Sarkodie T, Nolan L, et al
    Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
    JAMA Oncol. 2024;10:475-483.
    PubMed     Abstract available


    March 2024
  47. ITO K, Suzuki Y, Sakaguchi T, Fujiwara K, et al
    Physical Activity Using a Wearable Device as an Alternative to Performance Status in Patients With Advanced Lung Cancer.
    JAMA Oncol. 2024 Mar 28. doi: 10.1001/jamaoncol.2024.0023.
    PubMed     Abstract available


  48. TSUKITA Y, Tozuka T, Kushiro K, Hosokawa S, et al
    Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Mar 7. doi: 10.1001/jamaoncol.2023.6277.
    PubMed     Abstract available


  49. PALMA DA, Bahig H, Hope A, Harrow S, et al
    Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical Trial.
    JAMA Oncol. 2024 Mar 7. doi: 10.1001/jamaoncol.2023.7269.
    PubMed     Abstract available


  50. KEREKES DM, Frey AE, Prsic EH, Tran TT, et al
    Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US.
    JAMA Oncol. 2024;10:342-351.
    PubMed     Abstract available


    January 2024
  51. ARRIETA O, Cardenas-Fernandez D, Rodriguez-Mayoral O, Gutierrez-Torres S, et al
    Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial.
    JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.5232.
    PubMed     Abstract available


  52. LESTER-COLL NH, Park HS
    Stereotactic Body Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer-Is This the Future?
    JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.5856.
    PubMed    


  53. WU TC, Luterstein E, Neilsen BK, Goldman JW, et al
    Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.6033.
    PubMed     Abstract available


  54. NOGUEIRA LM, Liu Y
    Wildfire Exposure and Lung Cancer Survival-Reply.
    JAMA Oncol. 2024 Jan 4. doi: 10.1001/jamaoncol.2023.6126.
    PubMed    


  55. OZAKI A, Murakami M, Leppold C
    Wildfire Exposure and Lung Cancer Survival.
    JAMA Oncol. 2024 Jan 4. doi: 10.1001/jamaoncol.2023.6123.
    PubMed    


  56. OKUMA Y, Kubota K, Shimokawa M, Hashimoto K, et al
    First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2024;10:43-51.
    PubMed     Abstract available


    December 2023
  57. WEST HJ, Kim JY
    Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.
    JAMA Oncol. 2023 Dec 28. doi: 10.1001/jamaoncol.2023.5276.
    PubMed     Abstract available


  58. SHIRAISHI Y, Kishimoto J, Sugawara S, Mizutani H, et al
    Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2023 Dec 21. doi: 10.1001/jamaoncol.2023.5258.
    PubMed     Abstract available


  59. TEWARI KS, Colombo N, Monk BJ, Dubot C, et al
    Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses from the KEYNOTE-826 Randomized Clinical Trial.
    JAMA Oncol. 2023 Dec 14. doi: 10.1001/jamaoncol.2023.5410.
    PubMed     Abstract available


  60. TAKEMURA N, Cheung DST, Fong DYT, Lee AWM, et al
    Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer: A Randomized Clinical Trial.
    JAMA Oncol. 2023 Dec 7. doi: 10.1001/jamaoncol.2023.5248.
    PubMed     Abstract available


    November 2023
  61. BONNER SN, Curley R, Love K, Akande T, et al
    Structural Racism and Lung Cancer Risk: A Scoping Review.
    JAMA Oncol. 2023 Nov 30. doi: 10.1001/jamaoncol.2023.4897.
    PubMed     Abstract available


  62. WANG VE, Gainor JF
    Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
    JAMA Oncol. 2023 Nov 22. doi: 10.1001/jamaoncol.2023.5004.
    PubMed    


  63. KIM TW, Bedard PL, LoRusso P, Gordon MS, et al
    Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
    JAMA Oncol. 2023;9:1574-1582.
    PubMed     Abstract available


  64. GENSHEIMER MF, Gee H, Shirato H, Taguchi H, et al
    Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
    JAMA Oncol. 2023;9:1525-1534.
    PubMed     Abstract available


    October 2023
  65. CHOI E, Ding VY, Luo SJ, Ten Haaf K, et al
    Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
    JAMA Oncol. 2023 Oct 26. doi: 10.1001/jamaoncol.2023.4447.
    PubMed     Abstract available


  66. SEQUIST LV, Warner ET, Yang CJ
    Improving Eligibility Criteria for Lung Cancer Screening-Promises, Challenges, and Unmet Needs.
    JAMA Oncol. 2023 Oct 26. doi: 10.1001/jamaoncol.2023.4410.
    PubMed    


  67. JEMAL A, Schafer EJ, Sung H, Bandi P, et al
    The Burden of Lung Cancer in Women Compared With Men in the US.
    JAMA Oncol. 2023 Oct 12. doi: 10.1001/jamaoncol.2023.4415.
    PubMed    


  68. TAKAHASHI N, Hao Z, Villaruz LC, Zhang J, et al
    Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
    JAMA Oncol. 2023 Oct 12. doi: 10.1001/jamaoncol.2023.4025.
    PubMed     Abstract available


    September 2023
  69. ALDEA M, Marinello A, Guyon D, Gazzah A, et al
    Prevalence of Thromboembolic Events in Patients With Non-Small Cell Lung Cancer and RET Fusions.
    JAMA Oncol. 2023 Sep 14. doi: 10.1001/jamaoncol.2023.3625.
    PubMed    


  70. TACHIHARA M, Tsujino K, Ishihara T, Hayashi H, et al
    Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
    JAMA Oncol. 2023 Sep 7. doi: 10.1001/jamaoncol.2023.3309.
    PubMed     Abstract available


  71. GRECO L
    Patients With Brain Metastases Deserve Better-A Hard-Won Perspective.
    JAMA Oncol. 2023;9:1197-1198.
    PubMed    


  72. SPAAS M, Sundahl N, Kruse V, Rottey S, et al
    Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2023;9:1205-1213.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.